Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

March 18, 2011 updated by: Abbott

Palivizumab (Synagis®) Post-marketing Surveillance Cohort Study in Children < 24 Months of Age With Hemodynamically Significant Congenital Heart Disease

Retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that did not receive palivizumab

Study Overview

Status

Completed

Conditions

Detailed Description

This is an observational, non-interventional, retrospective cohort study of infants with hemodynamically significant congenital heart disease (HSCHD) who were less than 24 months of age when the first dose of palivizumab was administered (CASES), and infants who were diagnosed with hemodynamically significant congenital heart disease but did not receive palivizumab in a historical respiratory syncytial virus (RSV) season during the first 24 months of life (CONTROLS). CASES are matched to CONTROLS based on RSV season, age, type of cardiac lesion, and type of prior corrective cardiac surgery. Subject medical records are reviewed for occurrences of the clinical end points of infection, arrhythmia, and/or death that meet criteria for serious adverse events. The groups will be compared for number and percent of subjects who experience these primary serious adverse events (both individually and collectively) during a defined 8-month chart review period.

Study Type

Observational

Enrollment (Actual)

2036

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Linz, Austria, 4020
        • Site Reference ID/Investigator# 6263
      • Vienna, Austria, 1090
        • Site Reference ID/Investigator# 7956
      • Vienna, Austria, 1100
        • Site Reference ID/Investigator# 9403
  • Belgium
      • Brussels, Belgium, 1200
        • Site Reference ID/Investigator# 17821
      • Gent, Belgium, 9000
        • Site Reference ID/Investigator# 18602
      • Leuven, Belgium, 3000
        • Site Reference ID/Investigator# 18601
  • France
      • Nantes, France, 44093
        • Site Reference ID/Investigator# 6244
      • Paris, France, 75019
        • Site Reference ID/Investigator# 6261
      • Paris, France, CEDEX 15
        • Site Reference ID/Investigator# 6245
      • Reims, France, 51092
        • Site Reference ID/Investigator#6260
  • Germany
      • Bad Oeynhausen, Germany, 32545
        • Site Reference ID/Investigator# 6280
      • Berlin, Germany, 10779
        • Site Reference ID/Investigator# 9621
      • Braunschweig, Germany, 38102
        • Site Reference ID/Investigator# 16361
      • Duisburg, Germany, 47137
        • Site Reference ID/Investigator# 6283
      • Essen, Germany, 45147
        • Site Reference ID/Investigator# 6272
      • Goettingen, Germany, 37075
        • Site Reference ID/Investigator# 6271
      • Munich, Germany, 81377
        • Site Reference ID/Investigator# 8277
      • Rostock, Germany, 18057
        • Site Reference ID/Investigator# 11182
      • St. Augustin, Germany, 53757
        • Site Reference ID/Investigator# 6249
  • Italy
      • Campobasso, Italy, 86100
        • Site Reference ID/Investigator# 6274
      • Florence, Italy, 50139
        • Site Reference ID/Investigator# 6276
      • Naples, Italy, 80100
        • Site Reference ID/Investigator# 4703
      • Padova, Italy, 35128
        • Site Reference ID/Investigator# 4910
      • Roma, Italy, 00165
        • Site Reference ID/Investigator# 14681
  • Norway
      • Trondheim, Norway, 7006
        • Site Reference ID/Investigator# 14802
  • Poland
      • Bydgoszcz, Poland, 85-168
        • Site Reference ID/Investigator# 6275
      • Katowice, Poland, 40-752
        • Site Reference ID/Investigator# 13102
      • Krakow, Poland, 3-663
        • Site Reference ID/Investigator# 6270
      • Warsaw, Poland, 04-730
        • Site Reference ID/Investigator# 12222
  • Slovenia
      • Ljubljana, Slovenia, 1525
        • Site Reference ID/Investigator# 14682
  • Spain
      • A Coruna, Spain, 15006
        • Site Reference ID/Investigator# 5372
      • Madrid, Spain, 28009
        • Site Reference ID/Investigator# 15381
      • Madrid, Spain, 28034
        • Site Reference ID/Investigator# 15702
      • Santiago de Compostela, Spain, 15706
        • Site Reference ID/Investigator# 15261
  • United Kingdom
      • Belfast, United Kingdom, BT12 6BE
        • Site Reference ID/Investigator# 6282
      • Bristol, United Kingdom, BS2 8BJ
        • Site Reference ID/Investigator# 13941
      • London, United Kingdom, SW3 6NP
        • Site Reference ID/Investigator# 5023

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 2 years (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Children less than 24 months of age with hemodynamically significant congenital heart disease

Description

Inclusion Criteria:

  1. Subject must have documented hemodynamically significant congenital heart disease (Note: Children with uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus are not eligible).
  2. Subject must have unoperated or partially corrected congenital heart disease.
  3. Subject must have received at least one dose of palivizumab for prophylaxis during the Respiratory Syncytial Virus season - September 1 through April 30 (CASES), or would have been considered eligible for palivizumab prophylaxis (CONTROLS).
  4. Subject must be < 24 months of age at the time of the first dose of palivizumab prophylaxis (CASES) or < 32 months of age at the end of the assigned Respiratory Syncytial Virus season in which they would have been eligible to receive palivizumab if the drug had been approved in the European Union (CONTROLS).
  5. Subject's parent, guardian, or legal representative has voluntarily signed and dated a Release of Information Form to allow the review of medical records and collection of pertinent study data.

Exclusion Criteria:

  1. Subject was contraindicated for treatment with palivizumab according to the current European product label.
  2. Subject had full correction of Congenital Heart Disease.
  3. Subject received palivizumab before approval for use in Congenital Heart Disease (CASES), or subject received palivizumab at any time (CONTROLS).
  4. Subject has already been included in this study in a prior Respiratory Syncytial Virus season.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Palivizumab-treated subjects (CASES)
HSCHD infants, <2 yrs old at first dose of palivizumab
Non-palivizumab-treated subjects (CONTROLS)
HSCHD infants, <2 yrs old that did not receive palivizumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death
Time Frame: 8-month chart review period in CASES and CONTROLS
The number of subjects who experienced at least 1 event of infection, arrhythmia, or death meeting any of the criteria for a serious adverse event
8-month chart review period in CASES and CONTROLS
Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection.
Time Frame: 8-month chart review period in CASES and CONTROLS
The number of subjects who experienced at least 1 event of infection meeting any of the criteria for a serious adverse event
8-month chart review period in CASES and CONTROLS
Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Arrhythmia
Time Frame: 8-month chart review period in CASES and CONTROLS
The number of subjects who experienced at least 1 event of arrhythmia meeting any of the criteria for a serious adverse event
8-month chart review period in CASES and CONTROLS
Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Death
Time Frame: 8-month chart review period in CASES and CONTROLS
The number of subjects who died
8-month chart review period in CASES and CONTROLS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Abbott

Investigators

  • Study Director: Andrew Campbell, MD, Medical Director, Abbott Laboratories

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2006

Primary Completion (ACTUAL)

January 1, 2010

Study Completion (ACTUAL)

January 1, 2010

Study Registration Dates

First Submitted

February 23, 2010

First Submitted That Met QC Criteria

February 23, 2010

First Posted (ESTIMATE)

February 25, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

March 23, 2011

Last Update Submitted That Met QC Criteria

March 18, 2011

Last Verified

March 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • M03-681

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Severe Respiratory Syncytial Virus Infection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe